Research
Hormonal
GLP-1 receptor agonists or co-agonists have demonstrated substantial and sustained weight loss along with notable improvements in cardiometabolic markers.
Practitioners may consider GLP-1 receptor agonists as effective options for weight management and improving cardiometabolic health.
StrongSupportsmedium confidence
Liraglutide, semaglutide, and tirzepatide...have demonstrated substantial and sustained weight loss along with notable improvements in cardiometabolic markers.
Why this rating
Based on randomized trials mentioned in the abstract.
Source
Cardiovascular effects of anti-obesity medications: the perils and promise
Haoyi Zheng · Cardiology Plus · 2025
reviewCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →